TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38902928

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine and 10 mg hydrocortisone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: COMPARATOR
Intervention: 10 mg yohimbine
Number of subjects: 165

Group type: COMPARATOR
Intervention: 10 mg hydrocortisone
Number of subjects: 165
Study: 38902952

Group type: EXPERIMENTAL
Intervention: Chemotherapy received locally
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chemotherapy received locally
Number of subjects: 0
Study: 38902994

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (150 mg/m2 in D1), oxaliplatin (85 mg/m2 in D1), S-1/leucovorin (35 mg/m2 and 30 mg bid from D1 to D7)
Number of subjects: 19
Study: 38903022

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study: 38903173

Group type: EXPERIMENTAL
Intervention: Concurrent taVNS
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sequential taVNS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 150
Study: 38903416

Group type: EXPERIMENTAL
Intervention: VR treatment (3D with binaural beats)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition (2D with no binaural beats)
Number of subjects: 21
Study: 38903523

Group type: EXPERIMENTAL
Intervention: LVRNA012 mRNA vaccine (100ug)
Number of subjects: 2615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2615
Study: 38903809

Group type: EXPERIMENTAL
Intervention: REACHing Equity curriculum delivered virtually in three facilitated, interactive sessions over 7-9 weeks.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: REACHing Equity curriculum
Number of subjects: 37
Study: 38904119

Group type: EXPERIMENTAL
Intervention: rESWT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: sham-rESWT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: advice plus customised foot orthoses
Number of subjects: 200
Study: 38904126

Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioural support sessions based on the 5As algorithm and a 6-week supply of nicotine replacement therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active referral to the Maltese National Health Service's one-to-one smoking cessation support service based on motivational interviewing
Number of subjects: 100
Study: 38904129

Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Fasting residual C-peptide secretion
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Overall C-peptide levels
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Stimulated residual C-peptide
Number of subjects: 611
Study: 38904136

Group type: EXPERIMENTAL
Intervention: mHealth remote patient monitoring (RPM)-based care handoff model
Number of subjects: 0
Study: 38904139

Group type: EXPERIMENTAL
Intervention: A-DIVA Scale alone
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Algorithm for catheter placement
Number of subjects: 794
Study: 38904165

Group type: EXPERIMENTAL
Intervention: E4/DRSP (estetrol 15 mg)
Number of subjects: 1553
Study: 38904223

Group type: EXPERIMENTAL
Intervention: Ceramide-16 (Cer-16)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Ceramide-20 (Cer-20)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Ceramide-22 (Cer-22)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Ceramide-24 (Cer-24)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Sphingomyelin-16 (SM-16)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Sphingomyelin-20 (SM-20)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Sphingomyelin-22 (SM-22)
Number of subjects: 2688

Group type: EXPERIMENTAL
Intervention: Sphingomyelin-24 (SM-24)
Number of subjects: 2688
Study: 38904251

Group type: EXPERIMENTAL
Intervention: Measurement of serum levels of 4123 unique proteins using a modified aptamer proteomic assay.
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Baseline proteins including B2M, TIMP1, SERPINA4, and SVEP1.
Number of subjects: 1117

Group type: EXPERIMENTAL
Intervention: Proteomic risk score derived in patients with HFpEF.
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Comparison with published analyses in 2515 patients with heart failure with reduced ejection fraction from PARADIGM-HF and ATMOSPHERE trials.
Number of subjects: 1117
Study: 38904277

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 40
Study: 38904646

Group type: EXPERIMENTAL
Intervention: NT-proBNP <125 pg/mL
Number of subjects: 3480

Group type: COMPARATOR
Intervention: NT-proBNP ≥125 pg/mL
Number of subjects: 3480
Study: 38904657

Group type: EXPERIMENTAL
Intervention: Physical activity measured using accelerometry data from the MotionWatch 8
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Subjective reports of activities of daily living and other types of physical activity
Number of subjects: 204
Study: 38904749

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg and 2 mg
Number of subjects: 131
Study: 38904892

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) with concomitant G-CSF
Number of subjects: 230
Study: 38904899

Group type: EXPERIMENTAL
Intervention: Amberen (dietary supplement)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 38904908

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²) in CAN present group
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²) in CAN absent group
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Increasing BMI in CAN present group
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Increasing BMI in CAN absent group
Number of subjects: 7789
Study: 38904918

Group type: EXPERIMENTAL
Intervention: EVE + EXE (10 mg/day + 25 mg/day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: PBO + EXE (placebo + 25 mg/day)
Number of subjects: 159
Study: 38905143

Group type: EXPERIMENTAL
Intervention: CT-P47 via auto-injector (AI)
Number of subjects: 314

Group type: COMPARATOR
Intervention: CT-P47 via pre-filled syringe (PFS)
Number of subjects: 314
Study: 38905148

Group type: EXPERIMENTAL
Intervention: PIEB settings (PIEBnb = 29.4 minutes, PIEBi = 59.8 minutes, PIEBv = 6.2 mL)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: PCEA (volume 6 mL every 10 minutes)
Number of subjects: 69
Study: 38905174

Group type: EXPERIMENTAL
Intervention: Simple exercise program
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comprehensive exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39
Study: 38905212

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for ADHD-I (CADDI)
Number of subjects: 14
Study: 38905476

Group type: EXPERIMENTAL
Intervention: Couple-based care and treatment intervention
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Standard of care services
Number of subjects: 1080
Study: 38905520

Group type: EXPERIMENTAL
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo Surgery
Number of subjects: 146
Study: 38905569

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145-mg tablets daily or alternate days for those with impaired renal function)
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1151

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 1151
Study: 38905580

Group type: EXPERIMENTAL
Intervention: Topical capsaicin (2 g of capsaicin ointment 0.075%) applied four times a day for 5 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (matching ointment)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 38905608

Group type: EXPERIMENTAL
Intervention: Delicate mint toothpaste (n = 20)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mint toothpaste (n = 12)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Mint mouthwash (n = 20)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Delicate mint toothpaste, mint mouthwash, and an antimicrobial toothbrush (n = 20)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual oral care products and routine (control group; n = 12)
Number of subjects: 84
Study: 38905632

Group type: COMPARATOR
Intervention: Original (unflavored) on! nicotine pouch product
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Complete flavor profile (Berry, Cinnamon, Citrus, Coffee, Mint, Original, Wintergreen) of on! nicotine pouch products
Number of subjects: 400
Study: 38905635

Group type: EXPERIMENTAL
Intervention: JNJ-75276617 (bleximenib)
Number of subjects: 0
Study: 38905928

Group type: EXPERIMENTAL
Intervention: Reversal/replacement agent administration during hospitalization (specific agents not detailed).
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Historic cohort data collection from hospitalization to discharge for patients admitted for major bleeds during FXai use.
Number of subjects: 4000
Study: 38905959

Group type: EXPERIMENTAL
Intervention: Interactive education programme (e-learning and a two-day course)
Number of subjects: 368
Study: 38906161

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 755

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 755
Study: 38906178

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Regular cow milk formula
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Cow milk antibody concentrations in cord blood
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Cow milk antibody concentrations longitudinally from birth to 3 years
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Frequent liquid milk consumption after infancy
Number of subjects: 2159
Study: 38906210

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Delayed relugolix CT
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 38906425

Group type: EXPERIMENTAL
Intervention: Specialty palliative care
Number of subjects: 23
Study: 38906440

Group type: EXPERIMENTAL
Intervention: Random forest advanced fibrosis model
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Random forest cirrhosis model
Number of subjects: 1198
Study: 38906453

Group type: EXPERIMENTAL
Intervention: Computer-assisted open exposure of palatally impacted canines using a surgical template
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (freehand method)
Number of subjects: 100
Study: 38906462

Group type: EXPERIMENTAL
Intervention: Fine particulate matter (PM2.5)
Number of subjects: 5746

Group type: EXPERIMENTAL
Intervention: Inhalable particulate matter (PM10)
Number of subjects: 5746

Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2)
Number of subjects: 5746

Group type: COMPARATOR
Intervention: Sulfur dioxide (SO2)
Number of subjects: 5746

Group type: COMPARATOR
Intervention: Carbon monoxide (CO)
Number of subjects: 5746

Group type: COMPARATOR
Intervention: Ozone (O3)
Number of subjects: 5746
Study: 38906611

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Non-tailored feedback
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 1178
Study: 38906614

Group type: EXPERIMENTAL
Intervention: Insulin-and-pramlintide closed-loop system with simple meal announcements
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin-and-placebo system with carbohydrate counting
Number of subjects: 30
Study: 38906707

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100U
Number of subjects: 55

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 25U
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50U
Number of subjects: 55
Study: 38906793

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (LMWH 14%, UFH 8%, SCDs 43%)
Number of subjects: 862

Group type: COMPARATOR
Intervention: No thromboprophylaxis (21% contraindicated due to thrombocytopenia, 14% lacked documentation)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: SOFA score on the first ICU day
Number of subjects: 862
Study: 38906970

Group type: EXPERIMENTAL
Intervention: QL1209
Number of subjects: 585

Group type: COMPARATOR
Intervention: Pertuzumab
Number of subjects: 585
Study: 38907052

Group type: EXPERIMENTAL
Intervention: Narrow-diameter tissue level implant in T2DM patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Narrow-diameter tissue level implant in normoglycemic patients
Number of subjects: 26
Study: 38907104

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (starting dose 160 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38907106

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE) infusion at 15-20 mikrg/min adjusted until preload was restored (SVV < 12%)
Number of subjects: 20
Study: 38907120

Group type: EXPERIMENTAL
Intervention: Cytosorb® (CS) for myoglobin elimination
Number of subjects: 20
Study: 38907138

Group type: EXPERIMENTAL
Intervention: Non-melanoma skin cancers (NMSC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benign tumors (BT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no NMSC or BT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 200
Study: 38907159

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab, dabrafenib and trametinib
Number of subjects: 0
Study: 38907160

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 23
Study: 38907175

Group type: COMPARATOR
Intervention: Eliapixant (25 mg, 75 mg, and 150 mg) administered as an oral amorphous solid dispersion immediate-release tablet.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 36
Study: 38907254

Group type: EXPERIMENTAL
Intervention: Collaborative care involving community pharmacists
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care without community pharmacist involvement
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study: 38907310

Group type: EXPERIMENTAL
Intervention: Winter swimming
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (sedentary males)
Number of subjects: 23
Study: 38907320

Group type: EXPERIMENTAL
Intervention: Minimally invasive (ministernotomy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100
Study: 38907331

Group type: EXPERIMENTAL
Intervention: Rapid Implementation Feedback (RIF) report
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: RIF report findings
Number of subjects: 125
Study: 38907342

Group type: EXPERIMENTAL
Intervention: Selumetinib treatment
Number of subjects: 4
Study: 38907380

Group type: EXPERIMENTAL
Intervention: VR-guided meditation
Number of subjects: 10
Study: 38907679

Group type: EXPERIMENTAL
Intervention: rhPro-UK 35 mg (15 mg bolus + 20 mg infusion/30 min)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: rt-PA 0.9 mg/kg (10% bolus + 90% infusion/1 h)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: rhPro-UK 35 mg
Number of subjects: 1552
Study: 38907784

Group type: EXPERIMENTAL
Intervention: Participative problem-solving intervention aimed to reduce sick-leave
Number of subjects: 197

Group type: COMPARATOR
Intervention: Care as usual (CAU) involving any kind of work-directed interventions
Number of subjects: 197
Study: 38906616

Group type: EXPERIMENTAL
Intervention: GSU-Pulmonary Score (developed from 13 candidate predictor variables)
Number of subjects: 86231

Group type: EXPERIMENTAL
Intervention: GSU-Pulmonary Score
Number of subjects: 86231

Group type: EXPERIMENTAL
Intervention: LASSO regression
Number of subjects: 86231

Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 86231
Study: 38907877

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 500

Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 500
Study: 38907886

Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10-enhanced 3-T MRI
Number of subjects: 27
Study: 38907935

Group type: EXPERIMENTAL
Intervention: Insulin efsitora alfa (efsitora)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Insulin glargine (glargine)
Number of subjects: 54
Study: 38908553

Group type: EXPERIMENTAL
Intervention: Epithelium-off CXL protocol using a UV-A medical device with theranostic software, 0.22% riboflavin for 15 minutes, 9 minutes of UV-A irradiance at 10 mW/cm²
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epithelium-on CXL protocol using a UV-A medical device with theranostic software, 0.22% riboflavin for 20 minutes, 9 minutes of UV-A irradiance at 10 mW/cm²
Number of subjects: 50
Study: 38908733

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) at weeks 0, 2, 4, and 8; n = 30
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group; n = 30
Number of subjects: 60
Study: 38908840

Group type: EXPERIMENTAL
Intervention: Manas por Manas intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 400
Study: 38908841

Group type: EXPERIMENTAL
Intervention: ePRO intervention (responsive web application for weekly symptom reporting with proactive follow-up by nurses for 6 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ePRO intervention
Number of subjects: 50
Study: 38908843

Group type: EXPERIMENTAL
Intervention: Y-Check health and well-being check-up programme involving screening, on-the-spot care, and referral.
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Y-Check health and well-being check-up programme.
Number of subjects: 6000
Study: 38908842

Group type: EXPERIMENTAL
Intervention: 6-month supervised strength exercise intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 38908848

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study: 38909093

Group type: EXPERIMENTAL
Intervention: Horticultural therapy alongside usual care
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 211
Study: 38909144

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day for approximately 80% of patients, 15 mg/day for the remaining patients)
Number of subjects: 5717
Study: 38909157

Group type: EXPERIMENTAL
Intervention: Chest shield (with aluminum foil)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham shield (without aluminum foil)
Number of subjects: 140
Study: 38909189

Group type: EXPERIMENTAL
Intervention: Tartarase dentifrice (used twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tartarase dentifrice (used with dental tray for 30 min, then brushed again once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crest Cavity Protection (control dentifrice)
Number of subjects: 40
Study: 38909201

Group type: EXPERIMENTAL
Intervention: Normobaric intermittent hypoxia (fraction of inspired oxygen 0.16 for 5 min interspersed with 5 min normoxia), 45 min, 3 times a week for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Normobaric intermittent hypoxia
Number of subjects: 40
Study: 38909215

Group type: EXPERIMENTAL
Intervention: Partnering to Achieve School Success (PASS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study: 38909229

Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical anesthetic gel
Number of subjects: 64
Study: 38909352

Group type: EXPERIMENTAL
Intervention: eTEP
Number of subjects: 60

Group type: COMPARATOR
Intervention: RS
Number of subjects: 60
Study: 38909349

Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate-tauroursodeoxycholic acid (PB-TUDCA)
Number of subjects: 0
Study: 38909671

Group type: EXPERIMENTAL
Intervention: Microdissection testicular sperm extraction (micro-TESE)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Pre-SR hormonal stimulation
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Baseline follicle-stimulating hormone levels
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Presence of clinical varicocele
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: History of previous varicocelectomy
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Pre-micro-TESE testosterone levels
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Delta T (absolute increase in T levels from baseline)
Number of subjects: 616
Study: 38909712

Group type: EXPERIMENTAL
Intervention: Lung transplantation (LT)
Number of subjects: 31
Study: 38909740

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg weekly oral
Number of subjects: 93

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily oral
Number of subjects: 93
Study: 38909877

Group type: EXPERIMENTAL
Intervention: Tafamidis treatment
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Tafamidis untreated
Number of subjects: 1441
Study: 38909994

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 40
Study: 38909998

Group type: EXPERIMENTAL
Intervention: ChitoCare gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 42
Study: 38910002

Group type: EXPERIMENTAL
Intervention: Vaginal application of Vagifem 30 µg once a day for 14 days prior to colposcopy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo once a day for 14 days prior to colposcopy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vaginal application of Vagifem 30 µg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 38910112

Group type: EXPERIMENTAL
Intervention: Recorded maternal voice played into the infant incubator between 15 and 21 days of life
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no recorded maternal voice intervention)
Number of subjects: 40
Study: 38910197

Group type: EXPERIMENTAL
Intervention: 1.1-mm cryoprobe
Number of subjects: 224

Group type: COMPARATOR
Intervention: 1.9-mm cryoprobe
Number of subjects: 224